{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T21:11:31Z","timestamp":1762377091039,"version":"build-2065373602"},"reference-count":48,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,3,21]],"date-time":"2023-03-21T00:00:00Z","timestamp":1679356800000},"content-version":"am","delay-in-days":354,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["celltherapyjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytotherapy"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1016\/j.jcyt.2021.10.002","type":"journal-article","created":{"date-parts":[[2022,1,15]],"date-time":"2022-01-15T07:21:47Z","timestamp":1642231307000},"page":"428-436","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Time to initiation of pre-emptive therapy for cytomegalovirus impacts overall survival in pediatric hematopoietic stem cell transplant recipients"],"prefix":"10.1016","volume":"24","author":[{"given":"Christine","family":"Camacho-Bydume","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3236-6093","authenticated-orcid":false,"given":"Audrey","family":"Mauguen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5714-680X","authenticated-orcid":false,"given":"M. Irene","family":"Rodriguez-Sanchez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth","family":"Klein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1417-1823","authenticated-orcid":false,"given":"Nancy A.","family":"Kernan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4175-5728","authenticated-orcid":false,"given":"Susan","family":"Prockop","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2232-6952","authenticated-orcid":false,"given":"Jaap Jan","family":"Boelens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Genovefa A.","family":"Papanicolaou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Cancio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcyt.2021.10.002_bib0001","doi-asserted-by":"crossref","first-page":"e177","DOI":"10.1016\/j.bbmt.2020.04.013","article-title":"Current Use of and Trends in Hematopoietic Cell Transplantation in the United States","volume":"26","author":"D'Souza","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jcyt.2021.10.002_bib0002","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1016\/j.bbmt.2017.04.018","article-title":"Hematopoietic Stem Cell Transplantation Activity in Pediatric Cancer between 2008 and 2014 in the United States: A Center for International Blood and Marrow Transplant Research Report","volume":"23","author":"Khandelwal","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jcyt.2021.10.002_bib0003","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1007\/s00277-019-03755-2","article-title":"Age-dependent determinants of infectious complications profile in children and adults after hematopoietic cell transplantation: lesson from the nationwide study","volume":"98","author":"Czyzewski","year":"2019","journal-title":"Ann Hematol"},{"key":"10.1016\/j.jcyt.2021.10.002_bib0004","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.jmii.2015.07.011","article-title":"Risk factors and outcomes of cytomegalovirus viremia in pediatric hematopoietic stem cell transplantation patients","volume":"50","author":"Wu","year":"2017","journal-title":"J Microbiol Immunol Infect"},{"key":"10.1016\/j.jcyt.2021.10.002_bib0005","doi-asserted-by":"crossref","first-page":"e13109","DOI":"10.1111\/petr.13109","article-title":"The impact of alternative donor types on viral infections in pediatric hematopoietic stem cell transplantation","volume":"22","author":"Atay","year":"2018","journal-title":"Pediatr Transplant"},{"key":"10.1016\/j.jcyt.2021.10.002_bib0006","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1016\/j.bbmt.2016.04.004","article-title":"Cytomegalovirus Infection in Pediatric Hematopoietic Stem Cell Transplantation: Risk Factors for Primary Infection and Cases of Recurrent and Late Infection at a Single Center","volume":"22","author":"Rowe","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jcyt.2021.10.002_bib0007","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1128\/CVI.00697-14","article-title":"Seroprevalence of cytomegalovirus among children 1 to 5 years of age in the United States from the National Health and Nutrition Examination Survey of 2011 to 2012","volume":"22","author":"Lanzieri","year":"2015","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.jcyt.2021.10.002_bib0008","doi-asserted-by":"crossref","first-page":"e408","DOI":"10.1093\/cid\/ciaa1168","article-title":"Changes in Cytomegalovirus Seroprevalence Among U.S. Children Aged 1 to 5 Years: The National Health and Nutrition Examination Surveys","volume":"72","author":"Petersen","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jcyt.2021.10.002_bib0009","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1097\/MPH.0000000000000730","article-title":"Cytomegalovirus Treatment in Pediatric Hematopoietic Stem Cell Transplant Patients","volume":"39","author":"Wattles","year":"2017","journal-title":"J Pediatr Hematol Oncol"},{"key":"10.1016\/j.jcyt.2021.10.002_bib0010","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1086\/652438","article-title":"Cytomegalovirus seroprevalence in the United States: the national health and nutrition examination surveys, 1988-2004","volume":"50","author":"Bate","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jcyt.2021.10.002_bib0011","first-page":"6551","article-title":"Risk Factors for Cytomegalovirus Infection After Allogeneic Hematopoietic Cell Transplantation in Malignancies: Proposal for Classification","volume":"37","author":"Dziedzic","year":"2017","journal-title":"Anticancer Res"},{"key":"10.1016\/j.jcyt.2021.10.002_bib0012","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1182\/blood.2019000956","article-title":"How I treat CMV reactivation after allogeneic hematopoietic stem cell transplantation","volume":"135","author":"Einsele","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2021.10.002_bib0013","doi-asserted-by":"crossref","first-page":"17230","DOI":"10.18632\/oncotarget.7347","article-title":"Impact of cytomegalovirus reactivation on relapse and survival in patients with acute leukemia who received allogeneic hematopoietic stem cell transplantation in first remission","volume":"7","author":"Yoon","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.jcyt.2021.10.002_bib0014","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.bbmt.2015.09.006","article-title":"Effect of Cytomegalovirus Reactivation on Relapse after Allogeneic Hematopoietic Stem Cell Transplantation in Pediatric Acute Leukemia","volume":"22","author":"Inagaki","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jcyt.2021.10.002_bib0015","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1111\/bjh.12875","article-title":"Relationship between cytomegalovirus (CMV) reactivation, CMV-driven immunity, overall immune recovery and graft-versus-leukaemia effect in children","volume":"166","author":"Jeljeli","year":"2014","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jcyt.2021.10.002_bib0016","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1182\/blood-2015-11-679639","article-title":"Early cytomegalovirus reactivation remains associated with increased transplant-related mortality in the current era: a CIBMTR analysis","volume":"127","author":"Teira","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2021.10.002_bib0017","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1182\/bloodadvances.2019000814","article-title":"Heterogeneous impact of cytomegalovirus reactivation on nonrelapse mortality in hematopoietic stem cell transplantation","volume":"4","author":"Kaito","year":"2020","journal-title":"Blood Adv"},{"issue":"Suppl 2","key":"10.1016\/j.jcyt.2021.10.002_bib0018","doi-asserted-by":"crossref","first-page":"S43","DOI":"10.1038\/bmt.2015.95","article-title":"Prockop S. T-cell depleted allogeneic hematopoietic cell transplants as a platform for adoptive therapy with leukemia selective or virus-specific T-cells","volume":"50","author":"O'Reilly","year":"2015","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jcyt.2021.10.002_bib0019","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1016\/j.bbmt.2016.05.003","article-title":"Cytomegalovirus Infection after CD34(+)-Selected Hematopoietic Cell Transplantation","volume":"22","author":"Huang","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jcyt.2021.10.002_bib0020","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1182\/blood.V93.2.467","article-title":"Comparison of immune reconstitution after unrelated and related T-cell-depleted bone marrow transplantation: effect of patient age and donor leukocyte infusions","volume":"93","author":"Small","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2021.10.002_bib0021","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1097\/01.mph.0000174242.80167.9d","article-title":"Cytomegalovirus reactivation in pediatric hemopoietic progenitors transplant: a retrospective study on the risk factors and the efficacy of treatment","volume":"27","author":"Patel","year":"2005","journal-title":"J Pediatr Hematol Oncol"},{"key":"10.1016\/j.jcyt.2021.10.002_bib0022","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1111\/j.1399-3062.2007.00235.x","article-title":"Predictors for persistent cytomegalovirus reactivation after T-cell-depleted allogeneic hematopoietic stem cell transplantation","volume":"9","author":"Almyroudis","year":"2007","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.jcyt.2021.10.002_bib0023","doi-asserted-by":"crossref","first-page":"e14172","DOI":"10.1097\/MD.0000000000014172","article-title":"Factors associated with cytomegalovirus infection in children undergoing allogeneic hematopoietic stem-cell transplantation","volume":"98","author":"Jaing","year":"2019","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.jcyt.2021.10.002_bib0024","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1016\/j.bbmt.2016.05.014","article-title":"Risk Factors and Utility of a Risk-Based Algorithm for Monitoring Cytomegalovirus, Epstein-Barr Virus, and Adenovirus Infections in Pediatric Recipients after Allogeneic Hematopoietic Cell Transplantation","volume":"22","author":"Rustia","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jcyt.2021.10.002_bib0025","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.bbmt.2018.10.011","article-title":"Cytomegalovirus Infection Incidence and Risk Factors Across Diverse Hematopoietic Cell Transplantation Platforms Using a Standardized Monitoring and Treatment Approach: A Comprehensive Evaluation from a Single Institution","volume":"25","author":"Melendez-Munoz","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jcyt.2021.10.002_bib0026","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40121-017-0180-z","article-title":"Who Is the Patient at Risk of CMV Recurrence: A Review of the Current Scientific Evidence with a Focus on Hematopoietic Cell Transplantation","volume":"7","author":"Styczynski","year":"2018","journal-title":"Infect Dis Ther"},{"key":"10.1016\/j.jcyt.2021.10.002_bib0027","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.hoc.2010.11.011","article-title":"Cytomegalovirus in hematopoietic stem cell transplant recipients","volume":"25","author":"Ljungman","year":"2011","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.jcyt.2021.10.002_bib0028","first-page":"131","article-title":"CMV viral load kinetics as surrogate endpoints after allogeneic transplantation","author":"Duke","year":"2021","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jcyt.2021.10.002_bib0029","doi-asserted-by":"crossref","first-page":"5711","DOI":"10.1182\/blood-2008-10-143560","article-title":"How we treat cytomegalovirus in hematopoietic cell transplant recipients","volume":"113","author":"Boeckh","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2021.10.002_bib0030","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1056\/NEJMoa1706640","article-title":"Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation","volume":"377","author":"Marty","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcyt.2021.10.002_bib0031","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1002\/pbc.25355","article-title":"A survey of infectious disease clinical practices among pediatric blood and marrow transplant programs in the United States","volume":"62","author":"Abdel-Azim","year":"2015","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.jcyt.2021.10.002_bib0032","doi-asserted-by":"crossref","first-page":"e12881","DOI":"10.1111\/tid.12881","article-title":"Cytomegalovirus resistance in CD34(+) -selected hematopoietic cell transplant recipients","volume":"20","author":"Kim","year":"2018","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.jcyt.2021.10.002_bib0033","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1093\/cid\/ciw668","article-title":"Definitions of Cytomegalovirus Infection and Disease in Transplant Patients for Use in Clinical Trials","volume":"64","author":"Ljungman","year":"2017","journal-title":"Clin Infect Dis"},{"year":"2019","series-title":"R: A language and environment for statistical computing","key":"10.1016\/j.jcyt.2021.10.002_bib0034"},{"key":"10.1016\/j.jcyt.2021.10.002_bib0035","unstructured":"Gerds T. Prodlim: Product-limit estimation for censored event history analysis. R package version 2019;11:132019."},{"key":"10.1016\/j.jcyt.2021.10.002_bib0036","unstructured":"Gordon M, Seifert R. Greg: Regression Helper Functions. R package version 1.3.1 2019. https:\/\/CRAN.R-project.org\/package=Greg."},{"key":"10.1016\/j.jcyt.2021.10.002_bib0037","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.3390\/ijms20112666","article-title":"Cytomegalovirus Infections after Hematopoietic Stem Cell Transplantation: Current Status and Future Immunotherapy","volume":"20","author":"Cho","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jcyt.2021.10.002_bib0038","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1016\/j.bbmt.2016.05.020","article-title":"Impact of Donor and Recipient Cytomegalovirus Serostatus on Outcomes of Antithymocyte Globulin-Conditioned Hematopoietic Cell Transplantation","volume":"22","author":"Kalra","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jcyt.2021.10.002_bib0039","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/j.bbmt.2007.03.009","article-title":"Ganciclovir inhibits lymphocyte proliferation by impairing DNA synthesis","volume":"13","author":"Battiwalla","year":"2007","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jcyt.2021.10.002_bib0040","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1016\/j.bbmt.2012.05.015","article-title":"Efficacy of a viral load-based, risk-adapted, preemptive treatment strategy for prevention of cytomegalovirus disease after hematopoietic cell transplantation","volume":"18","author":"Green","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jcyt.2021.10.002_bib0041","doi-asserted-by":"crossref","first-page":"e119","DOI":"10.1016\/S2352-3026(15)00289-6","article-title":"Cytomegalovirus viral load and mortality after haemopoietic stem cell transplantation in the era of pre-emptive therapy: a retrospective cohort study","volume":"3","author":"Green","year":"2016","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.jcyt.2021.10.002_bib0042","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1093\/infdis\/jiab212","article-title":"Cytomegalovirus viral load kinetics predict cytomegalovirus end-organ disease and mortality after hematopoietic cell transplant","volume":"224","author":"Stern","year":"2021","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jcyt.2021.10.002_bib0043","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1182\/blood-2003-10-3616","article-title":"The impact of cytomegalovirus serostatus of donor and recipient before hematopoietic stem cell transplantation in the era of antiviral prophylaxis and preemptive therapy","volume":"103","author":"Boeckh","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2021.10.002_bib0044","doi-asserted-by":"crossref","first-page":"6009","DOI":"10.21873\/anticanres.12950","article-title":"Impact of CMV and EBV on Immune Recovery After Allogeneic Hematopoietic Cell Transplantation in Children","volume":"38","author":"Pukownik","year":"2018","journal-title":"Anticancer Res"},{"key":"10.1016\/j.jcyt.2021.10.002_bib0045","doi-asserted-by":"crossref","first-page":"4049","DOI":"10.1007\/s00018-015-1986-z","article-title":"The immune response to cytomegalovirus in allogeneic hematopoietic stem cell transplant recipients","volume":"72","author":"Ciaurriz","year":"2015","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.jcyt.2021.10.002_bib0046","doi-asserted-by":"crossref","first-page":"518.e1","DOI":"10.1016\/j.jtct.2021.03.003","article-title":"Cytomegalovirus Prophylaxis versus Pre-emptive Strategy: Different CD4(+) and CD8(+) T Cell Reconstitution after Allogeneic Hematopoietic Stem Cell Transplantation","volume":"27","author":"Sperotto","year":"2021","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jcyt.2021.10.002_bib0047","doi-asserted-by":"crossref","first-page":"263","DOI":"10.2478\/ahp-2020-0046","article-title":"Primary prophylaxis with letermovir for prevention of CMV infection in two children","volume":"51","author":"Styczynski","year":"2020","journal-title":"Acta Haematologica Polonica"},{"key":"10.1016\/j.jcyt.2021.10.002_bib0048","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1038\/s41409-020-01166-w","article-title":"Use of letermovir in off-label indications: Infectious Diseases Working Party of European Society of Blood and Marrow Transplantation retrospective study","volume":"56","author":"Styczy\u0144ski","year":"2020","journal-title":"Bone Marrow Transplant"}],"container-title":["Cytotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324921008549?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324921008549?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T01:45:54Z","timestamp":1761443154000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1465324921008549"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":48,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["S1465324921008549"],"URL":"https:\/\/doi.org\/10.1016\/j.jcyt.2021.10.002","relation":{},"ISSN":["1465-3249"],"issn-type":[{"type":"print","value":"1465-3249"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Time to initiation of pre-emptive therapy for cytomegalovirus impacts overall survival in pediatric hematopoietic stem cell transplant recipients","name":"articletitle","label":"Article Title"},{"value":"Cytotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcyt.2021.10.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 International Society for Cell & Gene Therapy. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}